

Pre-Clinical Studies

using MSCs from cord tissue

1. Troyer, D.L. & Weiss, M.L. Wharton's jelly-derived cells are a primitive stromal cell population. *Stem Cells* **26**, 591-9 (2008).
2. Can, A. & Karahuseyinoglu, S. Concise review: human umbilical cord stroma with regard to the source of fetus-derived stem cells. *Stem Cells* **25**, 2886-95 (2007).
3. Kode, J.A., Mukherjee, S., Joglekar, M.V. & Hardikar, A.A. Mesenchymal stem cells: immunobiology and role in immunomodulation and tissue regeneration. *Cytotherapy* **11**, 377-91 (2009).
4. Seshareddy, K., Troyer, D. & Weiss, M.L. Method to isolate mesenchymal-like cells from Wharton's Jelly of umbilical cord. *Methods Cell Biol* **86**, 101-19 (2008).
5. De Bruyn, C. et al. A Rapid, Simple, and Reproducible Method for the Isolation of Mesenchymal Stromal Cells from Wharton's Jelly Without Enzymatic Treatment. *Stem Cells Dev.*
6. Schneider, R.K. et al. Long-term survival and characterisation of human umbilical cord-derived mesenchymal stem cells on dermal equivalents. *Differentiation* **79**, 182-93.
7. Petsa, A., Gargani, S., Felesakis, A., Grigoriadis, N. & Grigoriadis, I. Effectiveness of protocol for the isolation of Wharton's Jelly stem cells in large-scale applications. *In Vitro Cell Dev Biol Anim* (2009).
8. Kadam, S.S., Tiwari, S. & Bhonde, R.R. Simultaneous isolation of vascular endothelial cells and mesenchymal stem cells from the human umbilical cord. *In Vitro Cell Dev Biol Anim* **45**, 23-7 (2009).
9. La Rocca, G. et al. Isolation and characterization of Oct-4+/HLA-G+ mesenchymal stem cells from human umbilical cord matrix: differentiation potential and detection of new markers. *Histochem Cell Biol* **131**, 267-82 (2009).
10. Pereira, W.C., Khushnooma, I., Madkaikar, M. & Ghosh, K. Reproducible methodology for the isolation of mesenchymal stem cells from human umbilical cord and its potential for cardiomyocyte generation. *J Tissue Eng Regen Med* **2**, 394-9 (2008).
11. Magin, A.S. et al. Primary cells as feeder cells for coculture expansion of human hematopoietic stem cells from umbilical cord blood--a comparative study. *Stem Cells Dev* **18**, 173-86 (2009).
12. Farias, V.A. et al. Human umbilical cord stromal stem cell express CD10 and exert contractile properties. *Placenta*.

13. Nekanti, U. et al. Optimization and scale-up of Wharton's jelly-derived mesenchymal stem cells for clinical applications. *Stem Cell Res* **5**, 244-54.
14. Fong, C.Y. et al. Derivation efficiency, cell proliferation, freeze-thaw survival, stem-cell properties and differentiation of human Wharton's jelly stem cells. *Reprod Biomed Online* **21**, 391-401.
15. Prasanna, S.J., Gopalakrishnan, D., Shankar, S.R. & Vasandan, A.B. Pro-inflammatory cytokines, IFN γ and TNF α , influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially. *PLoS One* **5**, e9016.
16. Penolazzi, L. et al. Influence of obstetric factors on osteogenic potential of umbilical cord-derived mesenchymal stem cells. *Reprod Biol Endocrinol* **7**, 106 (2009).
17. Nekanti, U. et al. Long-term expansion and pluripotent marker array analysis of Wharton's jelly-derived mesenchymal stem cells. *Stem Cells Dev* **19**, 117-30.
18. Bakhshi, T. et al. Mesenchymal stem cells from the Wharton's jelly of umbilical cord segments provide stromal support for the maintenance of cord blood hematopoietic stem cells during long-term ex vivo culture. *Transfusion* **48**, 2638-44 (2008).
19. Friedman, R. et al. Umbilical cord mesenchymal stem cells: adjuvants for human cell transplantation. *Biol Blood Marrow Transplant* **13**, 1477-86 (2007).
20. Wang, H.S. et al. Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord. *Stem Cells* **22**, 1330-7 (2004).
21. Kenar, H., Kose, G.T. & Hasirci, V. Design of a 3D aligned myocardial tissue construct from biodegradable polyesters. *J Mater Sci Mater Med* **21**, 989-97.
22. Breymann, C., Schmidt, D. & Hoerstrup, S.P. Umbilical cord cells as a source of cardiovascular tissue engineering. *Stem Cell Rev* **2**, 87-92 (2006).
23. Chen, M.Y., Lie, P.C., Li, Z.L. & Wei, X. Endothelial differentiation of Wharton's jelly-derived mesenchymal stem cells in comparison with bone marrow-derived mesenchymal stem cells. *Exp Hematol* **37**, 629-40 (2009).
24. Alaminos, M. et al. Transdifferentiation potentiality of human Wharton's jelly stem cells towards vascular endothelial cells. *J Cell Physiol* **223**, 640-7.
25. Hoerstrup, S.P. et al. Living, autologous pulmonary artery conduits tissue engineered from human umbilical cord cells. *Ann Thorac Surg* **74**, 46-52; discussion 52 (2002).
26. Fu, Y.S. et al. Conversion of human umbilical cord mesenchymal stem cells in Wharton's jelly to dopaminergic neurons in vitro: potential therapeutic application for Parkinsonism. *Stem Cells* **24**, 115-24 (2006).
27. Ma, L. et al. Human umbilical cord Wharton's Jelly-derived mesenchymal stem cells differentiation into nerve-like cells. *Chin Med J (Engl)* **118**, 1987-93 (2005).
28. Mitchell, K.E. et al. Matrix cells from Wharton's jelly form neurons and glia. *Stem Cells* **21**, 50-60 (2003).
29. Salgado, A.J. et al. Role of human umbilical cord mesenchymal progenitors conditioned media in neuronal/glial cell densities, viability, and proliferation. *Stem Cells Dev* **19**, 1067-74.

30. Zhang, H.T. et al. Human Wharton's jelly cells can be induced to differentiate into growth factor-secreting oligodendrocyte progenitor-like cells. *Differentiation* **79**, 15-20.
31. Schneider, R.K. et al. The role of biomaterials in the direction of mesenchymal stem cell properties and extracellular matrix remodelling in dermal tissue engineering. *Biomaterials* **31**, 7948-59.
32. Anzalone, R. et al. Wharton's Jelly Mesenchymal Stem Cells as Candidates for Beta Cells Regeneration: Extending the Differentiative and Immunomodulatory Benefits of Adult Mesenchymal Stem Cells for the Treatment of Type 1 Diabetes. *Stem Cell Rev.*
33. Chao, K.C., Chao, K.F., Fu, Y.S. & Liu, S.H. Islet-like clusters derived from mesenchymal stem cells in Wharton's Jelly of the human umbilical cord for transplantation to control type 1 diabetes. *PLoS One* **3**, e1451 (2008).
34. Wu, L.F., Wang, N.N., Liu, Y.S. & Wei, X. Differentiation of Wharton's jelly primitive stromal cells into insulin-producing cells in comparison with bone marrow mesenchymal stem cells. *Tissue Eng Part A* **15**, 2865-73 (2009).
35. Zhang, Y.N., Lie, P.C. & Wei, X. Differentiation of mesenchymal stromal cells derived from umbilical cord Wharton's jelly into hepatocyte-like cells. *Cytotherapy* **11**, 548-58 (2009).
36. Anzalone, R. et al. New emerging potentials for human Wharton's jelly mesenchymal stem cells: immunological features and hepatocyte-like differentiative capacity. *Stem Cells Dev* **19**, 423-38 (2010).
37. Gauthaman, K. et al. Osteogenic Differentiation of Human Wharton's Jelly Stem Cells on Nanofibrous Substrates In Vitro. *Tissue Eng Part A*.
38. Hou, T. et al. Umbilical cord Wharton's Jelly: a new potential cell source of mesenchymal stromal cells for bone tissue engineering. *Tissue Eng Part A* **15**, 2325-34 (2009).
39. Wang, L., Tran, I., Seshareddy, K., Weiss, M.L. & Detamore, M.S. A comparison of human bone marrow-derived mesenchymal stem cells and human umbilical cord-derived mesenchymal stromal cells for cartilage tissue engineering. *Tissue Eng Part A* **15**, 2259-66 (2009).
40. Wang, L., Singh, M., Bonewald, L.F. & Detamore, M.S. Signalling strategies for osteogenic differentiation of human umbilical cord mesenchymal stromal cells for 3D bone tissue engineering. *J Tissue Eng Regen Med* **3**, 398-404 (2009).
41. Schneider, R.K. et al. The osteogenic differentiation of adult bone marrow and perinatal umbilical mesenchymal stem cells and matrix remodelling in three-dimensional collagen scaffolds. *Biomaterials* **31**, 467-80.
42. Yoo, K.H. et al. Comparison of immunomodulatory properties of mesenchymal stem cells derived from adult human tissues. *Cell Immunol* **259**, 150-6 (2009).
43. Weiss, M.L. et al. Immune properties of human umbilical cord Wharton's jelly-derived cells. *Stem Cells* **26**, 2865-74 (2008).
44. Hirko, A.C., Dallsen, R., Jomura, S. & Xu, Y. Modulation of inflammatory responses after global ischemia by transplanted umbilical cord matrix stem cells. *Stem Cells* **26**, 2893-901 (2008).
45. Jomura, S. et al. Potential treatment of cerebral global ischemia with Oct-4+ umbilical cord matrix cells. *Stem Cells* **25**, 98-106 (2007).

46. Ding, D.C. et al. Enhancement of neuroplasticity through upregulation of beta1-integrin in human umbilical cord-derived stromal cell implanted stroke model. *Neurobiol Dis* **27**, 339-53 (2007).
47. Zhang, L. et al. Cografted Wharton's jelly cells-derived neurospheres and BDNF promote functional recovery after rat spinal cord transection. *Neurochem Res* **34**, 2030-9 (2009).
48. Lin, S.Z. et al. Transplantation of Human Wharton's Jelly-Derived Stem Cells Alleviates Chemically Induced Liver Fibrosis in Rats. *Cell Transplant*.
49. Tsai, P.C. et al. The therapeutic potential of human umbilical mesenchymal stem cells from Wharton's jelly in the treatment of rat liver fibrosis. *Liver Transpl* **15**, 484-95 (2009).
50. Ayuzawa, R. et al. Naive human umbilical cord matrix derived stem cells significantly attenuate growth of human breast cancer cells in vitro and in vivo. *Cancer Lett* **280**, 31-7 (2009).
51. Doi, C., Maurya, D.K., Pyle, M.M., Troyer, D. & Tamura, M. Cytotherapy with naive rat umbilical cord matrix stem cells significantly attenuates growth of murine pancreatic cancer cells and increases survival in syngeneic mice. *Cytotherapy* **12**, 408-17.
52. Ganta, C. et al. Rat umbilical cord stem cells completely abolish rat mammary carcinomas with no evidence of metastasis or recurrence 100 days post-tumor cell inoculation. *Cancer Res* **69**, 1815-20 (2009).
53. Maurya, D.K. et al. Therapy with un-engineered naive rat umbilical cord matrix stem cells markedly inhibits growth of murine lung adenocarcinoma. *BMC Cancer* **10**, 590.
54. Rachakatla, R.S., Marini, F., Weiss, M.L., Tamura, M. & Troyer, D. Development of human umbilical cord matrix stem cell-based gene therapy for experimental lung tumors. *Cancer Gene Ther* **14**, 828-35 (2007).
55. Rachakatla, R.S. et al. Combination treatment of human umbilical cord matrix stem cell-based interferon-beta gene therapy and 5-fluorouracil significantly reduces growth of metastatic human breast cancer in SCID mouse lungs. *Cancer Invest* **26**, 662-70 (2008).
56. Rachakatla, R.S. & Troyer, D. Wharton's jelly stromal cells as potential delivery vehicles for cancer therapeutics. *Future Oncol* **5**, 1237-44 (2009).
57. Moodley, Y. et al. Human umbilical cord mesenchymal stem cells reduce fibrosis of bleomycin-induced lung injury. *Am J Pathol* **175**, 303-13 (2009).